Skip to main content
. 2019 Sep 23;2019(9):CD013435. doi: 10.1002/14651858.CD013435

Materne 1985.

Methods RCT, parallel design
Participants Total number of randomized participants: 71
Inclusion criteria: elective CABG
Exclusion criteria: left ventricular ejection fraction < 40%, previous treatment with amiodarone, major perioperative complication (MI, cardiac tamponade), use of another anti‐arrhythmic drug
Type of surgery: elective CABG
Baseline characteristics (acebutolol)
Intervention group
  • Age, mean (SD): 55.1 (± 7.6) years

  • Gender, M/F: 28/4

  • Preoperative use of beta‐blockers, %: 65.6


Control group (standard care)
  • Age, mean (SD): 57.9 (± 6.9) years

  • Gender, M/F: 32/7

  • Preoperative use of beta‐blockers, %: 58.9


Country: Belgium
Setting: single centre; hospital
Interventions Intervention group (acebutolol)
  • Randomized, n = 32; losses = 0; analysed, n = 32 (use of ITT analysis not reported)

  • Details: initiated 24 h after surgery, 100 mg acebutolol IV or 600 mg orally during the 1st day, then 1200 mg/day orally. No end of the treatment period was specified


Control group (standard care)
  • Randomized, n = 39; losses = 0; analysed, n = 39

  • Details: standard care

Outcomes Outcomes measured/reported by study authors: supraventricular arrhythmias (to include AF), ventricular extrasystoles, haemodynamic parameters
Outcomes relevant to the review: AF
Notes Funding/declarations of interest: not reported
Study dates: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Not specified
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel (performance bias) 
 All outcomes High risk Open‐label trial
Blinding of outcome assessors (detection bias) 
 All outcomes High risk Open‐label trial
Incomplete outcome data (attrition bias) 
 All outcomes Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk Study authors did not report prospective clinical trial registration or publication of a protocol. It was not feasible to effectively assess risk of reporting bias
Other bias Low risk Not detected